A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
October 16th, 2018
Here, we present a protocol for the production and pre-clinical testing of murine CD19 CAR T cells by retroviral transduction and utilization as a therapy against established syngeneic A20 B-cell lymphoma in BALB/c mice with or without lymphodepleting pre-conditioning.
This method can help us answer key questions in the CAR T-cell immune therapy field, such as the genetic modification of CAR T-cells and combination with other immune therapies.The main advantage of this technique is that allows comparisons between the Lympho replete and the Lympho depleted settings.This allows us to see the role of endogenous immune cells in both disease progression and their interaction with therapeutic CAR T-cells.The implication of this technique as 10 to therapy on diagnosis of solid tumor because the lessons learned in this model can be directly translated to candy's house with other targets such as CEA.To begin this procedure.First, prepare all needed media and cells as outlined in the text protocol.On day one at complete DMEM to 15 square centimeter culture dishes.Seed 7.5 million platinum E-Cells in these dishes and incubate overnight at 37
Overview
This article presents a protocol for producing murine CD19 CAR T cells through retroviral transduction. It explores their application as a therapy against established syngeneic A20 B-cell lymphoma in BALB/c mice, with or without lymphodepleting pre-conditioning.
Key Study Components
Area of Science
- Immunotherapy
- Oncology
- Cellular Biology
Background
- CAR T-cell therapy is a promising approach in cancer treatment.
- Understanding the interaction between CAR T-cells and endogenous immune cells is crucial.
- The study focuses on comparing lympho-replete and lympho-depleted settings.
- Insights gained may be applicable to solid tumors and other therapeutic targets.
Purpose of Study
- To develop a protocol for generating CD19 CAR T cells.
- To evaluate the efficacy of these cells in treating lymphoma.
- To investigate the role of the immune environment in therapy outcomes.
Methods Used
- Preparation of media and cells as per the outlined protocol.
- Seeding of platinum E-Cells in culture dishes.
- Incubation of cells under controlled conditions.
- Assessment of CAR T-cell functionality in different immune settings.
Main Results
- Successful production of murine CD19 CAR T cells.
- Demonstrated differences in therapeutic efficacy based on immune conditioning.
- Insights into the role of endogenous immune cells in therapy response.
- Potential implications for broader applications in oncology.
Conclusions
- The protocol provides a valuable tool for CAR T-cell research.
- Findings contribute to understanding CAR T-cell interactions in vivo.
- Future studies may expand on these findings to improve cancer therapies.
Frequently Asked Questions
Executive Industry Relevance
This protocol enables preclinical evaluation of CD19 CAR T cells in a syngeneic mouse lymphoma model, supporting target validation and mechanistic de-risking in immuno-oncology pipelines. By comparing lymphoreplete and lymphodepleted settings, it informs predictive confidence in CAR T-cell efficacy and immune microenvironment interactions. The model supports early discovery decisions for CAR T-cell constructs and combination therapies before IND-enabling studies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of CAR T-cell constructs against established B-cell lymphoma to validate target engagement and antigen specificity.
- Operational Value: Provides a reproducible system for assessing CAR T-cell functionality ex vivo using flow cytometry, luminometry, and ELISA.
Screening & Assay Development
- Scientific Value: Generates validated murine CAR T cells for downstream screening of genetic modifications and cytokine arming (e.g., IL-12).
- Operational Value: Standardizes retroviral production and transduction workflows using Plat-E cells, MP71 constructs, and fibronectin-assisted centrifugation.
Translational & Preclinical Research
- Scientific Value: Tests CAR T-cell activity in vivo via bioluminescence imaging and disease progression tracking in systemic lymphoma models.
- Operational Value: Enables comparison of lymphoreplete and lymphodepleted conditions to de-risk therapeutic mechanisms and inform combination strategies.
Pipeline & Workflow Integration
This method fits within the discovery-to-preclinical continuum, supporting lead identification of CAR T-cell designs and informing preclinical validation through immune context modeling.
- Discovery Biology: Supports hypothesis testing of CAR T-cell mechanisms and endogenous immune cell interactions in lymphoma.
- Screening: Delivers standardized, quantifiable CAR T-cell products for reproducible assay conditions.
- Analytics: Employs bioluminescence, flow cytometry, and ELISA to generate comparative readouts across experimental groups.
- Translational Research: Models disease relevance in syngeneic hosts to bridge discovery and preclinical efficacy assessment.
- Enterprise Reuse: Establishes a reusable platform for evaluating CAR T-cell iterations, cytokine combinations, and adjunct therapies.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation and mechanistic insight into CAR T-cell/immune microenvironment dynamics.
- Operational Value: Reproducible CAR T-cell production and functional validation across ex vivo and in vivo readouts.
- Strategic Value: Informs go/no-go decisions by revealing lymphodepletion-dependent efficacy and combination therapy potential.
- Portfolio Impact: Enables risk-adjusted prioritization of CAR T-cell candidates based on immune context responsiveness.
Implementation Considerations
- Expertise in retroviral vector production, cell culture, and immunological assays.
- Access to platinum E-Cells, recombinant fibronectin fragments, and biosafety level 2 infrastructure.
- Standardization of transduction efficiency and CAR expression validation across batches.
- Adaptation considerations for different CAR constructs, target antigens, and murine lymphoma models.
- Practical limitations include model-specific antigen expression and murine immune system differences versus human physiology.
Biopharma FAQs
Chapters in this video
0:04
Title
0:55
Days 1 & 2: Preparation and Transfection of Plat-E Retroviral Packaging Cell Line
2:11
Day 3: Preparation of Virus-Containing Supernatant for Transduction and Isolation and In Vitro Activation of Mouse Splenic T Cells
4:27
Day 4: Transduction of Mouse T Cells
6:43
Day 5: Round 2 of Transduction
8:33
In Vitro Validation of CAR T Cell Activity
9:53
Results: Pre-Clinical Evaluation of CD19 CAR T Cells
11:32
Conclusion
